{
    "root": "2f2667cd-2ba2-1c58-e063-6394a90a9fc6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250227",
    "ingredients": [
        {
            "name": "CETOSTEARYL ALCOHOL",
            "code": "2DMT128M1S"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "ACACIA",
            "code": "5C5403N26O"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        }
    ],
    "indications": "carefully consider potential benefits risks diclofenac sodium extended release tablets , usp treatment options deciding diclofenac sodium extended-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac sodium extended-release tablets indicated : \u2022 relief signs symptoms osteoarthritis \u2022 relief signs symptoms rheumatoid arthritis",
    "contraindications": "carefully consider potential benefits risks diclofenac sodium extended-release tablets , usp treatment options deciding diclofenac sodium extended release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy diclofenac sodium extended-release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100 mg daily . relief rheumatoid arthritis , recommended 100 mg daily . rare patient diclofenac sodium extended-release tablets 100 mg/day unsatisfactory , dose may increased 100 mg twice day benefits outweigh risks increased side effects . different formulations diclofenac ( diclofenac sodium enteric-coated tablets ; diclofenac sodium extended-release tablets , usp , diclofenac potassium immediate-release tablets ) necessarily bioequivalent even milligram strength .",
    "warningsAndPrecautions": "diclofenac sodium extended-release tablets , usp 100 mg- pink round convex film coated tablet debossed dx 41 one side . ndc : 70518-1903-00 ndc : 70518-1903-01 packaging : 30 1 bottle plastic packaging : 60 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight container ( usp ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "diclofenac sodium extended-release tablets , usp contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic , ; exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium extended release tablets, USP and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals \n       \n \n  (see \n        \n  \n   \n                           WARNINGS;\u00a0\n        \n  \n   \n                        Gastrointestinal Bleeding, Ulceration, and Perforation)\n       \n \n  .\n      \n\n \n                  Diclofenac sodium extended-release tablets are indicated:\n                  \u2022 For relief of the signs and symptoms of osteoarthritis\n                   \u2022 For relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets, USP and other treatment options before deciding to use diclofenac sodium extended release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (\n       \n \n  see \n        \n  \n   WARNINGS\n                     ).\n      \n\n \n                  After observing the response to initial therapy with diclofenac sodium extended-release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 mg daily.\n                  For the relief of rheumatoid arthritis, the recommended dosage is 100 mg daily. In the rare patient where diclofenac sodium extended-release tablets 100 mg/day are unsatisfactory, the dose may be increased to 100 mg twice a day if the benefits outweigh the clinical risks of increased side effects.\n                   Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets, USP, diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac sodium extended-release tablets, USP\n                  100 mg- Pink round convex film coated tablet debossed with DX 41 on one side.\n                  NDC: 70518-1903-00\n                  NDC: 70518-1903-01\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature]. Protect from moisture.\n                  Dispense in tight container (USP).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Diclofenac sodium extended-release tablets, USP are contraindicated in the following patients:\n                  \n                     \n                        Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product \n         \n   \n    (see \n          \n    \n     WARNINGS; Anaphylactic Reactions, Serious Skin Reactions)\n         \n   \n    . \n        \n  \n   \n                     \n                     \n                        History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients \n         \n   \n    (see \n          \n    \n     WARNINGS; Anaphylactic Reactions,\u00a0\n          \n    \n     PRECAUTIONS; Exacerbation of Asthma Related to Aspirin Sensitivity)\n         \n   \n    .\n        \n  \n   \n                     \n                     \n                        In the setting of coronary artery bypass graft (CABG) surgery \n         \n   \n    (see \n          \n    \n     WARNINGS; Cardiovascular Thrombotic Events)\n         \n   \n    ."
}